Literature DB >> 18026859

P53 gene mutations in pituitary carcinomas.

Yoshinori Tanizaki1, Long Jin, Bernd W Scheithauer, Kalman Kovacs, Federico Roncaroli, Ricard V Lloyd.   

Abstract

Although p53 overexpression detected by immunohistochemistry has been reported in pituitary adenomas and carcinomas, genetic mutations in the p53 gene have not been previously detected in these tumors. We analyzed a series of eight pituitary adenomas and six pituitary carcinomas by immunohistochemistry, polymerase chain reaction amplification, and sequencing of p53 exon 5 through exon 8 for genetic mutations. Three carcinomas showed more than 20% expression of p53 protein in the tumor cells. One of these tumors with 60% overexpression of p53 protein had a mutation in codon 248, a common "hot spot" for p53 mutation, while the other carcinoma with 90% overexpression of p53 protein had a mutation in codon 135. All adenomas were negative for p53 mutations and had 15% of the cells expressing the p53 protein. Analysis of control tumors including four lung carcinomas with proven p53 mutations also had greater than 85% of the tumor cells overexpressing p53 protein. Two breast carcinoma cell lines with known p53 mutations, MBA-MD 231 and MBA-MD-486, also showed greater than 85% of the tumor cells overexpressing p53. These results show that p53 mutations are present in a subset of pituitary carcinomas and are usually associated with a high percentage of tumor cells overexpressing the p53 protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026859     DOI: 10.1007/s12022-007-9006-y

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  23 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

2.  Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity.

Authors:  Lijin Feng; Tongxiang Lin; Hiroaki Uranishi; Wei Gu; Yang Xu
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features.

Authors:  D R Walker; J P Bond; R E Tarone; C C Harris; W Makalowski; M S Boguski; M S Greenblatt
Journal:  Oncogene       Date:  1999-01-07       Impact factor: 9.867

Review 4.  Predictive markers of pituitary adenoma behavior.

Authors:  George Kontogeorgos
Journal:  Neuroendocrinology       Date:  2006-10-13       Impact factor: 4.914

Review 5.  Clinical implications of the p53 tumor-suppressor gene.

Authors:  C C Harris; M Hollstein
Journal:  N Engl J Med       Date:  1993-10-28       Impact factor: 91.245

Review 6.  Pituitary adenomas.

Authors:  Zoran Rumboldt
Journal:  Top Magn Reson Imaging       Date:  2005-07

7.  RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors.

Authors:  Nobuki Nakamura; J Aidan Carney; Long Jin; Sabine Kajita; Judit Pallares; Heyu Zhang; Xiang Qian; Thomas J Sebo; Lori A Erickson; Ricardo V Lloyd
Journal:  Lab Invest       Date:  2005-09       Impact factor: 5.662

8.  Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases.

Authors:  Thomas A Gaffey; Bernd W Scheithauer; Ricardo V Lloyd; Peter C Burger; Peter Robbins; Forouzandeh Fereidooni; Eva Horvath; Kalman Kovacs; Takao Kuroki; William F Young; Thomas J Sebo; Darren L Riehle; Allan J Belzberg
Journal:  J Neurosurg       Date:  2002-02       Impact factor: 5.115

Review 9.  Pituitary carcinoma: a review of the literature.

Authors:  Brian T Ragel; William T Couldwell
Journal:  Neurosurg Focus       Date:  2004-04-15       Impact factor: 4.047

10.  Database of p53 gene somatic mutations in human tumors and cell lines.

Authors:  M Hollstein; K Rice; M S Greenblatt; T Soussi; R Fuchs; T Sørlie; E Hovig; B Smith-Sørensen; R Montesano; C C Harris
Journal:  Nucleic Acids Res       Date:  1994-09       Impact factor: 16.971

View more
  34 in total

Review 1.  Clinical review: Pituitary carcinoma: difficult diagnosis and treatment.

Authors:  Anthony P Heaney
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 2.  Familial isolated pituitary adenomas: from genetics to therapy.

Authors:  Federica Guaraldi; Roberto Salvatori
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

3.  The Genomic Landscape of Sporadic Prolactinomas.

Authors:  Sunita M C De Sousa; Paul P S Wang; Stephen Santoreneos; Angeline Shen; Christopher J Yates; Milena Babic; Leila Eshraghi; Jinghua Feng; Barbara Koszyca; Samuel Roberts-Thomson; Andreas W Schreiber; David J Torpy; Hamish S Scott
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

4.  MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.

Authors:  George Kontogeorgos; Eleni Thodou; Mary Koutourousiou; Gregory Kaltsas; Andreas Seretis
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

Review 5.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 6.  Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Authors:  Akira Matsuno; Mineko Murakami; Katsumi Hoya; Shoko M Yamada; Shinya Miyamoto; So Yamada; Jae-Hyun Son; Hajime Nishido; Fuyuaki Ide; Hiroshi Nagashima; Mutsumi Sugaya; Toshio Hirohata; Akiko Mizutani; Hiroko Okinaga; Yudo Ishii; Shigeyuki Tahara; Akira Teramoto; R Yoshiyuki Osamura
Journal:  Med Mol Morphol       Date:  2013-08-17       Impact factor: 2.309

Review 7.  Management of aggressive pituitary adenomas and pituitary carcinomas.

Authors:  Anthony Heaney
Journal:  J Neurooncol       Date:  2014-03-02       Impact factor: 4.130

Review 8.  Genetics of Cushing's Syndrome.

Authors:  Laura C Hernández-Ramírez; Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2018-06       Impact factor: 4.741

9.  The Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor Shrinkage.

Authors:  Seda Turgut; Muzaffer Ilhan; Saime Turan; Ozcan Karaman; Ilhan Yaylim; Ozlem Kucukhuseyin; Ertugrul Tasan
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

10.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.